Results 151 to 160 of about 81,076 (308)

Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report

SAGE Open Medical Case Reports
Discoid lupus erythematosus is a chronic, recurring, autoimmune skin disease causing annular, scarring plaques on the head and neck. Deucravacitinib, a tyrosine kinase 2 inhibitor in the Janus kinase inhibitor family, represents an emerging treatment ...
Katherine Aw, Genevieve Gavigan
doaj   +1 more source

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO‐2b/3 and ALLEGRO‐LT Clinical Studies for Alopecia Areata

The Journal of Dermatology, EarlyView.
ABSTRACT Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies.
Rie Ueki, Masato Mizuashi, Kazutoshi Harada, Xingqi Zhang, Wenyu Wu, Wen‐Hung Chung, Ohsang Kwon, Xin Luo, Victoria Basey, Robert Wolk, Nanzhi Shi, Kayo Fujita, Yimeng Shen, Tomohiro Hirose   +13 more
wiley   +1 more source

Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT The efficacy and safety of ritlecitinib, a dual inhibitor of Janus kinase 3 (JAK3) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases, have been demonstrated in the ALLEGRO phase 2b/3 trial that enrolled patients aged ≥ 12 years with alopecia areata (AA) and ≥ 50% scalp hair loss.
Akira Yuasa, Kazumasa Kamei, Shota Saito, Masashi Mikami, Tatsunori Murata, Samantha Kiyomi Kurosky, Ernest H. Law, Kouki Nakamura, Rie Ueki   +8 more
wiley   +1 more source

Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib

Clinical, Cosmetic and Investigational Dermatology
Yingzhi Luo,1,* Jian Wu,2,* Xingyun Zhao,1,* Ping Yang,1 Yunmi Qiu,1 Liming Wu,1 Jianbo Zhong1 1Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang ...
Luo Y, Wu J, Zhao X, Yang P, Qiu Y, Wu L, Zhong J   +6 more
doaj  

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Club Cells in Nasal Epithelial Repair: Insights From an IL‐13‐Induced Inflammatory Model

Allergy, EarlyView.
Four inflammatory endotypes of CRSwNP, defined by eosinophil and neutrophil infiltration, show distinct patterns of basal, club, ciliated, and goblet cell expression in nasal epithelium. Using an ALI‐HNECs model, we demonstrate that IL‐13 impairs mucociliary function by promoting club‐to‐goblet cell differentiation while inhibiting club‐to‐ciliated ...
Zhi‐Qun Huang, Jing Liu, Jing Ye, Li‐Ying Sun, Hsiao Hui Ong, Yang Peng, Bing‐Qi Lin, Jun‐Hao Tu, Ke‐Shuang Wang, Yi‐Shan Xiong, Qing Luo, Mark Thong, Yu Xu, De‐Yun Wang   +13 more
wiley   +1 more source

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Use of Janus Kinase Inhibitor Upadacitinib in Microscopic Colitis. [PDF]

ACG Case Rep J
Mumm B, Stein DJ.
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Diversifying the triquinazine scaffold of a Janus kinase inhibitor. [PDF]

RSC Med Chem
Mulliri K, Meier K, Feuchter JD, Javor S, Meirelles MA, Reymond JL.   +5 more
europepmc   +1 more source